Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Gesine Meyer-Rath and Lise Jamieson.
Gesine Meyer-Rath
Connection Strength
5,511
Lise Jamieson
  1. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022 12; 9(12):e857-e867.
    View in: PubMed
    Score: 0,843
  2. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021 12 15; 35(Suppl 2):S173-S182.
    View in: PubMed
    Score: 0,792
  3. The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: a model analysis. BMJ Glob Health. 2021 07; 6(Suppl 4).
    View in: PubMed
    Score: 0,767
  4. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa. AIDS. 2020 05 01; 34(6):883-891.
    View in: PubMed
    Score: 0,708
  5. A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme. Vaccine. 2024 Aug 13; 42(20):125988.
    View in: PubMed
    Score: 0,235
  6. The role of modelling and analytics in South African COVID-19 planning and budgeting. PLOS Glob Public Health. 2023; 3(7):e0001063.
    View in: PubMed
    Score: 0,220
  7. What will it take for an injectable ARV to change the face of the HIV epidemic in high-prevalence countries? Considerations regarding drug costs and operations. J Int AIDS Soc. 2023 07; 26 Suppl 2:e26106.
    View in: PubMed
    Score: 0,220
  8. Differential in-hospital mortality and intensive care treatment over time: Informing hospital pathways for modelling COVID-19 in South Africa. PLOS Glob Public Health. 2023; 3(5):e0001073.
    View in: PubMed
    Score: 0,218
  9. Role of data from cost and other economic analyses in healthcare decision-making for HIV, TB and sexual/reproductive health programmes in South Africa. Health Policy Plan. 2021 Nov 11; 36(10):1545-1551.
    View in: PubMed
    Score: 0,197
  10. The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity. Clin Infect Dis. 2021 05 04; 72(9):1642-1644.
    View in: PubMed
    Score: 0,190
  11. The per-patient costs of HIV services in South Africa: Systematic review and application in the South African HIV Investment Case. PLoS One. 2019; 14(2):e0210497.
    View in: PubMed
    Score: 0,163
  12. Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. PLoS One. 2017; 12(10):e0186496.
    View in: PubMed
    Score: 0,149
  13. Designing an optimal HIV programme for South Africa: Does the optimal package change when diminishing returns are considered? BMC Public Health. 2017 01 31; 17(1):143.
    View in: PubMed
    Score: 0,141
  14. The long wait for long-acting HIV prevention and treatment formulations. Lancet HIV. 2024 Aug 16.
    View in: PubMed
    Score: 0,060
  15. Future HIV epidemic trajectories in South Africa and projected long-term consequences of reductions in general population HIV testing: a mathematical modelling study. Lancet Public Health. 2024 Apr; 9(4):e218-e230.
    View in: PubMed
    Score: 0,058
  16. The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants. AIDS. 2024 03 15; 38(4):589-594.
    View in: PubMed
    Score: 0,057
  17. A quantitative assessment of the consistency of projections from five mathematical models of the HIV epidemic in South Africa: a model comparison study. BMC Public Health. 2023 10 27; 23(1):2119.
    View in: PubMed
    Score: 0,056
  18. The National COVID-19 Epi Model (NCEM): Estimating cases, admissions and deaths for the first wave of COVID-19 in South Africa. PLOS Glob Public Health. 2023; 3(4):e0001070.
    View in: PubMed
    Score: 0,054
  19. Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models. Lancet Glob Health. 2023 Feb; 11(2):e244-e255.
    View in: PubMed
    Score: 0,053
  20. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models. Lancet Glob Health. 2022 09; 10(9):e1298-e1306.
    View in: PubMed
    Score: 0,052
  21. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV. 2022 05; 9(5):e353-e362.
    View in: PubMed
    Score: 0,051
  22. Inpatient Care Costs of COVID-19 in South Africa's Public Healthcare System. Int J Health Policy Manag. 2021 Apr 25.
    View in: PubMed
    Score: 0,047
  23. Potential Impact and Cost-Effectiveness of Condomless-Sex-Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance. J Infect Dis. 2021 04 23; 223(8):1345-1355.
    View in: PubMed
    Score: 0,047
  24. Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa. Open Forum Infect Dis. 2021 Mar; 8(3):ofab040.
    View in: PubMed
    Score: 0,047
  25. Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa. medRxiv. 2020 Sep 27.
    View in: PubMed
    Score: 0,046
  26. Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study. J Acquir Immune Defic Syndr. 2018 10 01; 79(2):195-205.
    View in: PubMed
    Score: 0,040
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.